Limaca Medical Ltd, an Israeli company that produces and distributes medical devices, announced on Tuesday the launch of its Precision-GI endoscopic automated motorised EUS biopsy device in the United States.

Commercialisation of the product is supported by Limaca's clinical trials, operational capabilities, FDA clearance and CMS Transitional Pass-Through (TPT) Payment award.

In trials, the product demonstrated its ability to offer consistent, high-quality biopsy samples, providing excellent tissue quality and procedural efficiency.

Limaca's Precision-GI endoscopic device is designed to obtain improved biopsy results for patients with suspected cancers in the GI tract and adjacent organs, including the pancreas, liver and other adjacent organs.

Dr Carlos Robles-Medranda, M.D., FASGE, AGAF from the IECED Medical Center, said: "The procedure with Precision GI is super easy for the physician and the results after just one pass are phenomenal – the core sample is not fragmented or bloody. It's very clear, it's impressive. The quality of the biopsy tissue is amazing. Having used core needles for many years, I haven't had samples that are not bloody, especially for example, with the liver. This will be very revolutionary for quality of tissue overall."